New High Blood Pressure Drug 1️⃣ Between 1950 and the mid-1960s, eight new classes of medication were first used. 2️⃣ The licensing of aprocitentan in 2024 represents the first new class of antihypertensive agent to become available since 2007 3️⃣ Aprocitentan, a new BP drug, is

Low-dose semaglutide reduced alcohol craving and consumption in adults with alcohol use disorder. ja.ma/3COtptq

Nikoli se nič ne spremeni? Dokler se ne. Vesela sem, ker je moja mama zdaj taka zanesenjakinja in kar poka od optimizma in energije. Po vseh letih depresivnih pogovorov, kako je vse strašno in kako se nič ne da. Piše Ivana Djilas, pisateljica. buff.ly/3COjioC

Finally out. This work is the result of a successful collaborative effort. Thanks to all contributors!

Interesting commentary on one of the most relevant and debated recent studies in breast oncology: SONIA. Are the results compelling enough to consider a delayed administration of CDK4/6-inhibitors for HR+/HER2- MBC? nature.com/articles/s4157…

The #SERENA6 phase 3 trial is positive: a switch to camizestrant + CDK4/6i (vs continuation of AI + CDK4/6i) upon emergence of ESR1 mutations led to a significant improvement in PFS. PFS2 and OS, which will be key to interpret the results, remain immature. astrazeneca.com/media-centre/p…

Oncologists on X are buzzing about the SERENA-6 trial. Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6

Catalyst: after $AZN's SERD success, $RHHBY looks to the front line. Via ApexOnco -> oncologypipeline.com/apexonco/node/… $OLMA $ARVN

BeiGene fleshes out global ambition as Brukinsa surpasses AstraZeneca's Calquence in quarterly sales fiercepharma.com/pharma/beigene…

Dejte mal svoje sindikaliste zdrmat; mi smo dobil še razlike od diskriminatornih božičnic nakazane. Pa ni blo to mal dnarja.

Brexpiprazole-sertraline combo worked better than either alone (or placebo) in new 4-arm trial of PTSD: pubmed.ncbi.nlm.nih.gov/40009045 In mice, brexpiprazole sharpened memory for real threats, while reducing the overgeneralized threat-response in #PTSD: pubmed.ncbi.nlm.nih.gov/32814812

Viewpoint: The growing use of immune checkpoint inhibitors in cancer treatment brings significant therapeutic benefits but also long-term immune-related adverse effects. ja.ma/4gYT8NR

Excellent review - Management of hepatocellular cancer ascopubs.org/doi/10.1200/OP… JCO Oncology Practice OncoAlert Ryan Nipp, MD, MPH, MBA, FASCO ASCO

📢 Our comprehensive review on post-progression treatment strategies after CDK4/6 inhibitor in HR+/HER2− MBC is now published in Cancer Treatment Reviews. Grateful to Deniz Can Guven and Sercan Aksoy, MD for their invaluable mentorship and support 🙏🏻 👉doi.org/10.1016/j.ctrv…

Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis fiercepharma.com/pharma/novarti…

💉Accelerated Infusion of Nivolumab and Pembrolizumab EORTC ✅Infusion in 10 minutes is safe 👉doi.org/10.1016/j.ejca… OncoAlert Dr Joseph McCollom DO #cancer #oncology #MedX

Quetiapine outperformed lithium augmentation, with similar tolerability, in 1-yr RCT of treatment resistant depression: ncbi.nlm.nih.gov/pubmed/40113355 Surprised? Well, quetiapine has unique anxiety/sleep benefits, and approached esketamine's efficacy in 32-wk trial.

🧵#pohvalanadan Če boste kdaj potrebovali odzivnega & prijaznega serviserja za belo tehniko (razen kuhalne tehnike) v Ljubljani. Že tretjič me je pronto rešil Servis Lamovec. V soboto sem celo pozabila, da so prazniki, a je vseeno odgovoril v eni uri, danes zjutraj pa že prišel.

Zakaj Slovenija cinca s prepovedjo solarijev za mladoletne dnevnik.si/novice/sloveni…

Merck will lay off 6,000, reducing workforce by 8% fiercepharma.com/pharma/merck-w…